Krsnaa Diagnostics Q1 FY27 Earnings Call Transcript Released
Krsnaa Diagnostics reported Q1 FY27 revenue of ₹2,355 million, up 22% YoY. The company secured the Himachal Pradesh CT project and saw its retail business grow 64% YoY to ₹193 million. EBITDA was ₹588 million (25% margin), impacted by Rajasthan project ramp-up costs. Retail is expected to be EBITDA positive by Q2 FY27.
The announcement provides an update on Q1 FY27 results and business developments, including new project wins and retail growth, which are positive indicators. However, it does not involve a major corporate action like a merger, acquisition, or significant fundraising that would warrant a 'HIGH' impact.
The company reported strong year-on-year revenue growth, secured a new significant project in Himachal Pradesh, and showed robust expansion in its retail business. Management expressed confidence in future growth and margin improvement.
Krsnaa Diagnostics Limited has released the transcript of its earnings conference call held on August 14, 2026, to discuss the Unaudited Financial Results for the quarter ended June 30, 2026. The call featured insights from Managing Director Mr. Yash Mutha, Group CEO Mr. Mitesh Dave, and Interim CFO Mr. Chandra Prakash.
During the call, Mr. Mutha highlighted a year-on-year revenue growth of approximately 22% in Q1 FY27, with like-to-like projects growing by approximately 12%. He also announced the award of the Himachal Pradesh CT project for 34 CT scans, which is expected to be a cash-paying project and strengthen revenue visibility for the next 10 years. The company's retail business showed significant growth, increasing by approximately 64% year-on-year, with its network expanding to over 4,000 touch points. Krsnaa Diagnostics is also preparing to launch a new offering that combines preventive diagnostics with financial protection.
Mr. Dave elaborated on the operational developments, including the Rajasthan projects moving into the operational phase with 31 Mother labs, 62 hub labs, and 1,228 collection centers. He also mentioned the inauguration of 8 MRI centers in Maharashtra and the addition of 12 new NABH Accreditations, bringing the total to 124. The retail business, leveraging an asset-light franchisee model, continues its strong growth trajectory.
Mr. Prakash reported that revenue from operations for Q1 FY27 stood at ₹2,355 million, a 22% year-on-year increase. EBITDA was ₹588 million with an EBITDA margin of 25%, impacted by upfront costs for manpower onboarding in Rajasthan. Profit After Tax (PAT) was ₹166 million, with a margin of 7%. The retail revenue grew by 64% year-on-year to ₹193 million, contributing approximately 9% to the overall group revenue. The company expects the retail business to become EBITDA positive by Q2 FY27.
During the Q&A session, management clarified that the 'fees to hospital' expense primarily relates to revenue sharing with local partners for projects like Rajasthan. They also discussed the revenue contribution from Rajasthan, expecting ₹100-150 crores annually, with potential to grow. The company is also focusing on driving growth through existing businesses, new PPP projects, the expanding retail segment, and innovative product launches. Margins are expected to improve as Rajasthan operations normalize, aiming for double-digit margins by the end of the year. The retail business is projected to grow exponentially by the end of the financial year.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under other investor communications. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.